HemoShear will receive an upfront payment and funding to develop a new human tissue-based model of a rare liver disease using the company’s REVEAL-Tx™ Platform.
AgroSpheres today announced a strategic alliance with Orion Integrated Biosciences to create the next generation of environmentally friendly, cost-effective and reliable RNAi pesticide products.
TearSolutions, Inc. Announces Results from Phase I/II trial of LacripepTM to Treat Primary Sjögren’s Syndrome and Appoints Anil Asrani President and CEO
TearSolutions, Inc. announced today the successful completion and preliminary outcomes of a Phase I/II trial of LacripepTM in Primary Sjögren’s Syndrome (PSS) patients.
Icarus Medical Innovations Reveals The Ascender, A Revolutionary Knee Brace that Aims to Change the Future of Aging Athletics and those who Suffer from Osteoarthritis.
By: Whitelaw Reid, UVA Today People of a certain age may be familiar with the line from the television commercial, “I’ve fallen and I can’t get up.” The ad was...
Charlottesville’s MicroGEM International has been awarded up to $40.9 million by the National Institutes of Health (NIH), Rapid Acceleration of Diagnostics (RADxSM) initiative to expedite the launch of the company’s...
With an ambitious vision for growth, advancing the organization mission, and deepening connection to the local community, CvilleBioHub announces the recent appointments of three board members to a newly expanded...
Next Gen Nutrition Investment Fund, LP (NGN) is pleased to announce a strategic investment in Bonumose LLC, which has developed and patented an enzymatic technology platform for continuous production of...
Charlottesville leaders focus on bolstering the regional entrepreneurial ecosystem in the biotech sector through new collaboration
As part of the collaboration, CAV Angels will engage early in the review process with CvilleBioHub to support founders and early stage concepts to streamline the pathway for funding resources.
UVA has selected 14 promising biomedical research projects to receive funding from the Ivy Foundation COVID-19 Translational Research Fund.
HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia
This award will enable HemoShear to have more frequent interactions with the FDA, as well as eligibility for accelerated approval, priority review, and rolling submission of a new drug application.